Integrin-Linked Kinase (ILK) Promotes Mitochondrial Dysfunction by Decreasing CPT1A Expression in a Folic Acid-Based...

Area of Science:

• Nephrology
• Molecular Biology
• Cell Biology

Background:

• Integrin-linked kinase (ILK) is a known factor in kidney damage pathogenesis.
• The specific role of ILK in renal mitochondrial dysfunction is not well understood.

Purpose of the Study:

• To investigate the role of ILK and its downstream signaling in folic acid-induced kidney injury and mitochondrial dysfunction.
• To explore ILK as a potential therapeutic target for kidney disease.

Main Methods:

• A folic acid (FA)-induced kidney disease model in wild-type and ILK conditional-knockdown (cKD-ILK) mice.
• In vitro studies using human kidney tubular epithelial cells (HK2) with siRNA-mediated gene silencing.
• Assessment of ILK, GSK3β, C/EBPβ, mitochondrial function markers, fibrosis, and autophagy markers using various molecular and cellular assays.

Main Results:

• Folic acid upregulated ILK, decreased GSK3β activity, increased fibrosis, and caused mitochondrial dysfunction in vivo and in vitro.
• ILK depletion reversed these detrimental effects, mitigating kidney damage.
• The ILK-GSK3β-C/EBPβ signaling axis regulates CPT1A transcription, impacting mitochondrial activity.

Conclusions:

• ILK plays a critical role in mediating renal damage and mitochondrial dysfunction.
• Targeting ILK can ameliorate kidney injury and preserve mitochondrial function.
• The ILK-GSK3β-C/EBPβ pathway is a key regulator of mitochondrial homeostasis in kidney disease.